Meropenem Kabi

Meropenem, the active ingredient in Meropenem Kabi, is a carbapenem antibiotic presented as a sterile powder for reconstitution for intravenous use. It treats severe Gram‑negative and Gram‑positive bacterial infections in hospitalized adult and pediatric patients and is indicated for a range of serious infections administered under medical supervision.

GNH USA supplies Meropenem Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The product meets EU quality standards and is manufactured under GMP conditions.

Meropenem is used to treat infections caused by susceptible bacteria across several clinical categories.

- Complicated intra‑abdominal infections: provides bacterial eradication in patients with peritonitis or intra‑abdominal abscesses. - Hospital‑acquired pneumonia, including ventilator‑associated pneumonia: achieves rapid clearance of pathogenic organisms in the lower respiratory tract. - Complicated urinary tract infections: resolves infection caused by resistant Gram‑negative uropathogens. - Bacterial meningitis: penetrates the cerebrospinal fluid to eliminate causative bacteria. - Septicemia and febrile neutropenia: offers broad‑spectrum coverage for life‑threatening bloodstream infections.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal discomfort. - Diarrhea: may be watery and self‑limiting. - Vomiting: occasional episodes during infusion. - Rash: erythematous skin eruptions. - Headache: transient cranial discomfort. - Elevated liver enzymes: transient increase in transaminases.

Serious or Rare Side Effects: - Seizures: especially in patients with renal impairment or high doses. - Clostridioides difficile‑associated colitis: severe diarrhea with pseudomembranous colitis. - Anaphylaxis: acute, potentially life‑threatening allergic reaction. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Renal toxicity: acute kidney injury in susceptible individuals. - Hematologic abnormalities: neutropenia or thrombocytopenia.

Careful assessment and monitoring are required before and during therapy.

- Renal function: adjust dose in patients with impaired clearance. - Neurological status: monitor for seizures, particularly in the elderly or those with CNS disorders. - Allergic history: avoid in patients with known β‑lactam hypersensitivity. - Concomitant antibiotics: assess for additive toxicity when used with other nephrotoxic or neurotoxic agents. - Pregnancy and lactation: use only if the potential benefit justifies the potential risk. - Storage: Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Drug interactions may affect efficacy or safety.

Major Interactions (Avoid): - Valproic acid: meropenem reduces serum valproate levels, risking seizure breakthrough. - Probenecid: may increase meropenem plasma concentrations, heightening toxicity risk. - Other carbapenems: concurrent use can increase neurotoxicity.

Moderate Interactions (Monitor Closely): - Aminoglycosides: combined nephrotoxic potential requires renal function monitoring. - Loop diuretics: may exacerbate electrolyte disturbances. - Warfarin: monitor INR as meropenem can alter anticoagulant effect.